Epigenomics said that it successfully completed a biomarker-discovery study with AstraZeneca last year, and that it will now test the potential of those markers to predict response to EGFR inhibitors such as AstraZeneca's Iressa in a panel of preclinical cancer models.
Under the terms of the agreement, Epigenomics will receive R&D fees and can participate in the development of any pharmacodiagnostic products resulting from the collaboration.
Further financial details were not disclosed.